ClinicalTrials.gg
Status unknownNCT03305705Updated Oct 13, 2017

Effect of Iron on Cerebral Dopamine Receptor Density in Non-anaemic Premenopausal Women With Low Ferritin and Fatigue

A Phase 4 interventional study of Iron Carboxymaltose and Sodium chloride 0.9% in Fatigue and Iron-deficiency, sponsored by Albina Nowak, MD. Status unknown at 1 site in Switzerland. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-10-13.

Sponsored by Albina Nowak, MD · Phase 4, Interventional, and Basic science

How we know

The sponsor has not verified this record recently (last verified Oct 2017), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 32 studies in Fatigue with a site in Switzerland — 6 open to participants now, 8 under way, 1 of them phase 3. Fatigue · Switzerland.

Planned enrollment
15th of 18
20 · median 69
Started
2017
with 3 others
Phase 4
4 of 32
none open now
Registered
13th of 32
by date
Lead sponsor
1 of 32
Albina Nowak, MD

Among the 32 studies in Fatigue with a site in Switzerland, this one is the 15th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2017, is one of 4 in phase 4, and was the 13th registered.

Fatigue

2,233 studies on the registry are indexed under Fatigue; 429 are open to participants now.

Browse Fatigue studies →

Open to participants now

6 of the 32 studies in Fatigue with a site in Switzerland are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 241 Fatigue studies recruiting now, 112 (46%) set no upper age limit and 99 (41%) stop at 75 or younger; 23 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 55 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Fatigue with a site in Switzerland, or all of them as a file.
02

Study summary

This study investigates the effect of intravenous iron substitution in non-anaemic premenopausal women with iron deficiency on:

  • Changes in the cerebral Dopamine (DA) receptor density after iron substitution, shown by brain PET
  • Reduction of fatigue and other neuropsychological symptoms after iron supplementation
03

Conditions studied

  • Fatigue
  • Iron-deficiency
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy female subjects, Age > 18 years, premenopausal, regularly menstruating
  • 18-25 kg/m2
  • Serum ferritin level \< 15 μg/ml, > 120 g/L
  • Adequate during the study period
  • Fatigue determined as 2 or more points in the basic questionnaire for fatigue

Exclusion criteria

Exclusion Criteria:

  • Day-night shift work
  • 11 or more points in the BDI
  • No psychiatric disease (as assessed by neuropsychiatric assessment)
  • 15 or more points in the ISI
  • Known to iron carboxymaltose, iron sucrose or iron sulfate
  • Intake of iron preparations during the last 8 weeks before the start of the trial protocol
  • Pregnancy or lactation
  • Any cardiovascular or pulmonary disease
  • Acute or chronic infection/inflammation or
  • Other obvious physical or psychiatric causes for fatigue (known mental disorders, e.g. depression)
  • Chronic intake of concurrent medication (especially antipsychotic drugs), except oral . Sporadic intake of NSAID or paracetamol, e.g. in the case of a common cold or sporadic headaches is allowed.
  • CRP > 10 mg/L
  • TSH out of normal range
  • Any concurrent medical condition(s) that, in the view of the investigator, would prevent compliance or participation or jeopardize the health of the patients.
  • Participation in any other therapeutic trial within the previous month
  • Known History of //
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment Arm 1

    Patients will be treated with 0.9% sodium chloride (placebo) at Visit 1 and with iron carboxymaltose in 6 weeks at Visit 2. The patients will be blinded with respect to the treatment sequence.

    Drug: Iron Carboxymaltose · Drug: Sodium chloride 0.9%

  • Experimental
    Treatment Arm 2

    Patients will be treated with 0.9% sodium chloride (placebo) at Visit 1 and with iron carboxymaltose in 6 weeks at Visit 2. The patients will be blinded with respect to the treatment sequence.

    Drug: Iron Carboxymaltose · Drug: Sodium chloride 0.9%

Interventions

06

What researchers measure

Primary outcomes

  1. Dopamine (DA) receptor density

    Changes in the cerebral Dopamine (DA) receptor density determined by brain PET with the 11C-Raclopride tracer

    Time frame: 6 weeks

Secondary outcomes

  1. Fatigue

    Reduction of fatigue after iron supplementation determined by Fatigue Assessment Scale (FAS)

    Time frame: 6 weeks

  2. Fatigue

    Reduction of fatigue after iron supplementation determined by "Würzburger Erschöpfungs-Inventar bei Multipler Sklerose" (WEIMuS, in German) questionaire

    Time frame: 6 weeks

  3. Neuropsychological symptoms

    Reduction of neuropsychological symptoms after iron supplementation determined by neuropsychological assessment

    Time frame: 6 weeks

07

Study locations

1 site
  • University Hospital Zurich
    Zürich, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2017; primary completion for Aug 2019, 22 months later.

Of 15 phase 4 interventional studies under Fatigue, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 55. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2017
First posted
Oct 10, 2017
StartEst.
Oct 23, 2017
Primary completionEst.
Aug 31, 2019
CompletionEst.
Aug 31, 2019
Last update
Oct 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03305705
Lead sponsor
Albina Nowak, MD
Responsible party
Albina Nowak, MD (senior physician, University of Zurich) — Sponsor-investigator
First posted
Oct 10, 2017
Start date
Oct 23, 2017 (estimated)
Primary completion
Aug 31, 2019 (estimated)
Completion
Aug 31, 2019 (estimated)
Last update
Oct 13, 2017

Study contacts

Albina Nowak, MD
Contact
albina.nowak@usz.ch
+41 (0)44 255 10 54
Albina Nowak, MD
principal investigator · University of Zurich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ferric carboxymaltose · Saline Solution

Start the discussion